CR20170022A - Anticuerpos biespecíficos anti-il4-il13 - Google Patents

Anticuerpos biespecíficos anti-il4-il13

Info

Publication number
CR20170022A
CR20170022A CR20170022A CR20170022A CR20170022A CR 20170022 A CR20170022 A CR 20170022A CR 20170022 A CR20170022 A CR 20170022A CR 20170022 A CR20170022 A CR 20170022A CR 20170022 A CR20170022 A CR 20170022A
Authority
CR
Costa Rica
Prior art keywords
fragments
double
antibody
region
binding proteins
Prior art date
Application number
CR20170022A
Other languages
English (en)
Inventor
Christina Soubrane
Arun Subramaniam
Corine Esperet
Alexandre Jagerschmiet
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CR20170022A publication Critical patent/CR20170022A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

En el presente documento se desvelan dosis seguras de proteínas de unión de tipo anticuerpo de doble región Vo fragmentos de las mismas, así como métodos para evaluar la unión de proteínas de tipo anticuerpo de doble región V o fragmentos de las mismas a sus dianas y métodos para tratar la fibrosis pulmonar idiopática (FPI) mediante la administración de dosis seguras de proteínas de unión de tipo anticuerpo de doble región V o fragmentos de las mismas. En algunas realizaciones, las proteínas de unión de tipo anticuerpo de doble región V o fragmentos de las mismas se unen tanto a la IL-4 como a la IL-13.
CR20170022A 2014-06-27 2015-06-26 Anticuerpos biespecíficos anti-il4-il13 CR20170022A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462018253P 2014-06-27 2014-06-27
EP14306477 2014-09-24
US201562102097P 2015-01-11 2015-01-11
PCT/IB2015/001377 WO2015198146A2 (en) 2014-06-27 2015-06-26 Anti-il4-il 13 bispecific antibodies

Publications (1)

Publication Number Publication Date
CR20170022A true CR20170022A (es) 2017-04-04

Family

ID=51663114

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170022A CR20170022A (es) 2014-06-27 2015-06-26 Anticuerpos biespecíficos anti-il4-il13

Country Status (18)

Country Link
US (2) US20170145089A1 (es)
EP (1) EP3160502A2 (es)
JP (1) JP2017530089A (es)
KR (1) KR102558891B1 (es)
CN (1) CN106573975A (es)
AU (1) AU2015278829B2 (es)
BR (1) BR112016030568B8 (es)
CA (1) CA2952902C (es)
CL (1) CL2016003317A1 (es)
CR (1) CR20170022A (es)
EA (1) EA201692495A8 (es)
MX (1) MX2017000171A (es)
NZ (1) NZ728020A (es)
PH (1) PH12016502569A1 (es)
SG (2) SG11201610594WA (es)
TN (1) TN2016000569A1 (es)
TW (2) TWI745962B (es)
WO (1) WO2015198146A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
TWI745962B (zh) 2014-06-27 2021-11-11 法商賽諾菲公司 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法
US11827671B2 (en) 2019-05-24 2023-11-28 Sanofi Methods for treating systemic sclerosis
WO2023166418A2 (en) * 2022-03-03 2023-09-07 Pfizer Inc. Multispecific antibodies and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
EP0338745B1 (en) 1988-04-16 1995-03-01 Celltech Limited Method for producing recombinant DNA proteins
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
JP2005512522A (ja) 2001-10-26 2005-05-12 セントカー・インコーポレーテツド Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用
US20040023338A1 (en) 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
WO2006042333A2 (en) 2004-10-12 2006-04-20 Xencor, Inc. Prediction and assessment of immunogenicity
AU2005307831A1 (en) 2004-11-17 2006-05-26 Amgen, Inc. Fully human monoclonal antibodies to IL-13
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2008087194A (ja) 2006-09-29 2008-04-17 Brother Ind Ltd インクジェットプリンタ
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2009069355A1 (ja) * 2007-11-28 2009-06-04 Riken Ｉｌ－１７ｒｂ陽性ｎｋｔ細胞を用いたアレルギー性気道炎症及び／又は気道過敏症の治療薬のスクリーニング方法
JP5439915B2 (ja) 2009-04-09 2014-03-12 ユニマテック株式会社 硬化性含フッ素ポリエーテル組成物
EP2427203B1 (en) * 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f antibodies and use thereof
JP5305366B2 (ja) 2009-10-26 2013-10-02 国立大学法人大阪大学 画像特徴抽出装置、画像特徴抽出方法、画像認識装置、及び画像認識方法
CN102640001A (zh) * 2009-11-05 2012-08-15 诺瓦提斯公司 预测纤维化进展的生物标记物
SG10201401746TA (en) 2010-12-16 2014-10-30 Genentech Inc Diagnosis And Treatments Relating To TH2 Inhibition
JP2014510730A (ja) 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
PL3470432T3 (pl) * 2012-08-21 2022-02-07 Sanofi Biotechnology Sposoby leczenia lub zapobiegania astmie przez podawanie antagonisty IL-4R
RU2698907C2 (ru) * 2012-09-07 2019-09-02 Ридженерон Фармасьютикалз, Инк. Способы лечения атопического дерматита с помощью антагониста il-4r
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
WO2015121318A1 (en) 2014-02-12 2015-08-20 Sanofi Anti-il-4/anti-il-13 bispecific antibody/polyglutamate formulations
TWI745962B (zh) 2014-06-27 2021-11-11 法商賽諾菲公司 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法

Also Published As

Publication number Publication date
CA2952902C (en) 2024-02-13
WO2015198146A3 (en) 2016-03-31
PH12016502569A1 (en) 2017-04-17
MX2017000171A (es) 2017-04-25
JP2017530089A (ja) 2017-10-12
EA201692495A8 (ru) 2017-07-31
US20190359703A1 (en) 2019-11-28
CL2016003317A1 (es) 2017-08-11
US20170145089A1 (en) 2017-05-25
CA2952902A1 (en) 2015-12-30
SG11201610594WA (en) 2017-01-27
SG10201811562YA (en) 2019-01-30
TN2016000569A1 (en) 2018-04-04
TWI745962B (zh) 2021-11-11
BR112016030568B1 (pt) 2023-10-17
EA201692495A1 (ru) 2017-05-31
WO2015198146A2 (en) 2015-12-30
TW201628647A (zh) 2016-08-16
NZ728020A (en) 2022-07-01
EP3160502A2 (en) 2017-05-03
BR112016030568B8 (pt) 2023-12-05
AU2015278829B2 (en) 2021-03-25
KR102558891B1 (ko) 2023-07-21
CN106573975A (zh) 2017-04-19
KR20170020519A (ko) 2017-02-22
BR112016030568A2 (pt) 2018-02-20
TW202034954A (zh) 2020-10-01
US11136388B2 (en) 2021-10-05
AU2015278829A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
EA201890630A1 (ru) Антитела против pd-1 и способы их применения
CY1124740T1 (el) Συνθεσεις που περιλαμβανουν συνθετiκα πολυνουκλεοτιδια που κωδικοποιουν crispr σχετικες πρωτεϊνες και συνθετικα sgrnas και μεθοδοι χρησης
CO2017013398A2 (es) Anticuerpos anti-ctla-4
PE20170665A1 (es) Anticuerpos anti-tau humanizados
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CY1122701T1 (el) Απελευθερωση πρωτεϊνης με βαση βακτηρια
BR112016022841A2 (pt) cadeia j modificada
EA201692098A1 (ru) Биокерамические композиции и их применение для биомодулирования
ECSP17045736A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
BR112016021034A2 (pt) Composição farmacêutica, uso de tal composição, método para tratar uma doença e kit
CY1123654T1 (el) Αποδεσμευση πρωτεϊνης me βαση βακτηρια
UY35718A (es) Anticuerpos anti-csf-1r: métodos de expresión de los mismos.
CR20170022A (es) Anticuerpos biespecíficos anti-il4-il13
ES2965033T3 (es) Métodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la pérdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de diabetes
MX2017007187A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
AR090668A1 (es) Anticuerpo anti-adamts-5, derivados y usos del mismo
CL2016002839A1 (es) Derivados de carboxamida
ECSP17013904A (es) Angiopoietin-like 4 antibodies and methods of use
CO2020005371A2 (es) Anticuerpos anti-apoc3 y métodos de uso de estos
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
BR112016019390A2 (pt) proteínas de fusão uti